After developing one of the first therapies to genetically engineer white blood cells to attack cancer, and then selling their company, Kite Pharma, to Gilead for $11.9 billion, what do Arie Belldegrun and David Chang do next?
After developing one of the first therapies to genetically engineer white blood cells to attack cancer, and then selling their company, Kite Pharma, to Gilead for $11.9 billion, what do Arie Belldegrun and David Chang do next?